Undifferentiated epithelial-rich invasive malignant thymoma: complete response to cisplatin, vinblastine, and bleomycin therapy.

Dy, Carlos; Mindán, Javier Pardo; Aparicio, Luís Antón; Algarra, Salvador Martín; Â, Gil; Gonzalez, F.; Harguindey, Salvador

doi:10.1200/jco.1988.6.3.536

Cited by 34 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dismal prognosis of patients with advanced thymic carcinoma has made it necessary to experiment with new treatment modalities 5, 19. Recently, a good response rate to chemotherapy has been reported in the literature7, 20, 21 and multimodal strategies have been advocated 5, 8, 9, 19. Lucchi et al reported the results of multimodality treatment including neoadjuvant chemotherapy, surgery, and postoperative radiotherapy 19.…”

Section: Discussionmentioning

confidence: 99%

“…In the current study, 4 patients with unresectable tumors at the time of presentation underwent complete resection with a good response using neoadjuvant chemotherapy, and all 4 patients were alive and free of disease with a follow‐up of 62–120 months. To our knowledge no recommended regimen of chemotherapy has been clearly established, although some authors have advocated a cisplatin‐ and/or doxorubicin‐based combination 7, 9, 11, 18, 20, 22. For advanced tumors that appear to be unresectable at the time of presentation, preoperative shrinkage of the thymic carcinoma by means of neoadjuvant chemotherapy may improve the resectability and, therefore, the survival rate.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment and prognosis of thymic carcinoma

Ogawa

Toita

Umemura

et al. 2002

Cancer

161

View full text Add to dashboard Cite

BACKGROUND Thymic carcinomas are rare neoplasms, and information regarding the results of treatment and possible prognostic factors in patients with these tumors is limited. METHODS The records of 40 patients with histologically confirmed thymic carcinoma who were treated between 1984 and 1998 were reviewed. Twenty‐seven patients were treated with surgical resection followed by radiotherapy with or without chemotherapy, and the remaining 13 patients were treated with radiotherapy with or without chemotherapy. The median follow‐up time for the 13 surviving patients was 87 months (range, 44–193 months). RESULTS The 5‐year and 10‐year actuarial overall survival rates in all patients were 38% and 28%, respectively. On univariate analysis, complete resection, Karnofsky performance status (KPS), histology, and Masaoka stage at the time of diagnosis were found to have a significant impact on overall survival, whereas on multivariate analysis, complete resection, KPS, and histology were found to be significant prognostic factors. With regard to the degree of resection, 12 of 16 patients (75%) treated with complete resection were alive and free of disease at the time of last follow‐up whereas 1 of 24 patients (4%) treated with incomplete resection or biopsy still was alive. Among 12 surviving patients treated with complete resection, 8 with resectable tumors at the time of presentation all had low‐grade histology (squamous cell carcinoma) and were treated successfully with complete resection and postoperative radiotherapy with or without adjuvant chemotherapy. The remaining four patients with unresectable tumors at the time of presentation were treated successfully with neoadjuvant chemotherapy, complete resection, and postoperative radiotherapy. CONCLUSIONS The results of the current study indicate that multimodal treatment, especially complete resection and postoperative radiotherapy with or without chemotherapy, is a curative therapy for thymic carcinomas. Cancer 2002;94:3115–9. © 2002 American Cancer Society. DOI 10.1002/cncr.10588

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Treatment and prognosis of thymic carcinoma

Ogawa

Toita

Umemura

et al. 2002

Cancer

161

View full text Add to dashboard Cite

show abstract

Treatment of pediatric malignant thymoma: Long-term remission in a 14-year-old boy with EBV-associated thymic carcinoma by aggressive, combined modality treatment

Niehues¹,

Harms

Jürgens

et al. 1996

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Malignant thymoma, including thymic carcinoma, is extremely uncommon in the pediatric population. It is known to have a very poor outcome. We report on a 14‐year‐old boy with Epstein‐Barr virus (EBV)‐associated thymic carcinoma. Sections of the original tumor were analyzed for EBV by in situ hybridization to confirm the histological diagnosis of a lymphoepithelioma‐like subtype. High copy numbers of EBV RNA were detected in the tumor tissue, suggesting an etiological role of EBV in our case. Intensive treatment resulted in long‐term remission over 12 years. In order to facilitate the difficult management of the rare child with malignant thymoma, a literature search was initiated. Forty well‐documented pediatric cases of malignant thymoma were found in the literature. Histological characteristics, clinical features, and therapeutic regimens were reviewed. Having the very limited experience with malignant thymoma in childhood in mind, it is concluded that its aggressiveness makes the most intensive treatment necessary. Long‐term remission can be achieved by application of radical surgery, high‐dose irradiation, and multiagent chemotherapy. The combination of cisplatinum, etoposide, and ifosfamide seems to be promising. © 1996 Wiley‐Liss, Inc.

show abstract